High-dose Erythropoietin for Asphyxia and Encephalopathy

Trial Profile

High-dose Erythropoietin for Asphyxia and Encephalopathy

Phase of Trial: Phase III

Latest Information Update: 08 Feb 2018

At a glance

  • Drugs Epoetin alfa (Primary)
  • Indications Asphyxia; Encephalopathy
  • Focus Therapeutic Use
  • Acronyms HEAL
  • Most Recent Events

    • 09 Jan 2017 Status changed from not yet recruiting to recruiting.
    • 28 Dec 2016 Planned primary completion date changed from 1 Jan 2022 to 1 Jun 2022.
    • 28 Dec 2016 Planned initiation date changed from 1 Sep 2016 to 1 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top